• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » PAVmed raises $1.5m in private placement

PAVmed raises $1.5m in private placement

February 2, 2017 By Fink Densford

PAVmedPAVmed Inc. (NSDQ:PAVMU) said today it raised $1.5 million through a private placement of Series A convertible preferred stock and Series A warrants, with funds slated to support FDA clearance of its 1st product, the PortIO intraosseous infusion system.

The New York-based company said it is hopeful for for FDA 510(k) clearance for the PortIO by the end of the 2nd quarter of 2017. PAVmed said it also plans to file a 510(k) premarket notification submission for its 2nd product, the CarpX percutaneous system for the treatment of Carpal Tunnel Syndrome, during the 2nd quarter.

“The strong investor interest in our company has been extremely gratifying. Furthermore, we continue to be delighted with investors’ growing receptivity and endorsement of our business model. We are excited about the near-term milestones for PortIO and CarpX. The combined addressable market opportunities for these products are in excess of $1 billion. We believe that the commercialization of these products has the potential to generate significant value for our shareholders. Our time and capital efficient business model enables our multi-product pipeline strategy.” CEO Dr. Lishan Aklog said in a press release.

The company said it estimates the cost to gain clearance and initiate commercialization for both products will be approximately $1 million.

Preferred stock sold in the round is convertible into PAVmed common shares at $6 per share, while each Series A warrant is exercisable for 1 share of common stock at $8 per share.

PAVmed said it will continue to evaluate potential exchange offers involving outstanding securities.

“We look forward to making further announcements about the forward momentum of other products in our pipeline. The alternatives currently being evaluated are intended to reward holders of our outstanding securities, provide additional incentives for long-term ownership of such securities and attract additional investors to our company,” Aklog said in a prepared statement.

Last November, PAVmed said it inked an exclusive licensing agreement with academic institutions to develop and commercialize antibiotic-eluting resorbable ear tubes based on an aqueous silk technology designed by the institutions.

The licensing deal includes agreements with Tufts University, Massachusetts Eye & Ear Infirmary and Massachusetts General Hospital, who developed the aqueous silk technology.

Filed Under: Business/Financial News Tagged With: Pavmed

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy